Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dawn Swan

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Journal of Thrombosis and Haemostasis : JTH|April 8, 2025
Direct oral anticoagulant failure in patients with venous thromboembolism-why and what next?Dawn Swan, Robert Turner, Erik Lerkevang Grove, et al.
Thrombosis Research|April 12, 2026
Thrombosis after surgical splenectomy - why, in whom and can we prevent it?Gerard Gurumurthy, Dawn Swan, Lara Roberts, et al.
Research and Practice in Thrombosis and Haemostasis|February 2, 2026
Clinical characteristics of thrombocytopenia in tropical diseases and management in resource-limited settingsGerard Gurumurthy, Juditha Gurumurthy, Samantha Gurumurthy, et al.
JCO Oncology Practice|May 29, 2026
Toxicity Under-Reporting in Early-Phase Plasma Cell Dyscrasia Clinical Trial AbstractsDawn Swan, Marsali Maclean, Niamh Waters, et al.
International Immunopharmacology|February 26, 2026
Cyclophosphamide-pomalidomide combination alters the tumour cell secretome and enhances the anti-myeloma activity of elotuzumab through NK cell-mediated cytotoxicityClaire L Feerick, Lei Lei, Dawn Swan, et al.
Cancer Immunology, Immunotherapy : CII|January 11, 2020
The CD38<sup>low</sup> natural killer cell line KHYG1 transiently expressing CD16<sup>F158V</sup> in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricideSubhashis Sarkar, Sachin K S Chauhan, John Daly, et al.
Cancers|April 13, 2023
Sialofucosylation Enables Platelet Binding to Myeloma Cells via P-Selectin and Suppresses NK Cell-Mediated CytotoxicityAlessandro Natoni, Marina Cerreto, Maria Stefania De Propris, et al.
Oncoimmunology|February 8, 2021
Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosisSerika D Naicker, Claire L Feerick, Kevin Lynch, et al.
British Journal of Haematology|February 15, 2022
Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019Dawn Swan, Patrick J Hayden, Dirk-Jan Eikema, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Journal of Thrombosis and Haemostasis : JTH|April 8, 2025
Direct oral anticoagulant failure in patients with venous thromboembolism-why and what next?Dawn Swan, Robert Turner, Erik Lerkevang Grove, et al.
Thrombosis Research|April 12, 2026
Thrombosis after surgical splenectomy - why, in whom and can we prevent it?Gerard Gurumurthy, Dawn Swan, Lara Roberts, et al.
Research and Practice in Thrombosis and Haemostasis|February 2, 2026
Clinical characteristics of thrombocytopenia in tropical diseases and management in resource-limited settingsGerard Gurumurthy, Juditha Gurumurthy, Samantha Gurumurthy, et al.
JCO Oncology Practice|May 29, 2026
Toxicity Under-Reporting in Early-Phase Plasma Cell Dyscrasia Clinical Trial AbstractsDawn Swan, Marsali Maclean, Niamh Waters, et al.
International Immunopharmacology|February 26, 2026
Cyclophosphamide-pomalidomide combination alters the tumour cell secretome and enhances the anti-myeloma activity of elotuzumab through NK cell-mediated cytotoxicityClaire L Feerick, Lei Lei, Dawn Swan, et al.
Cancer Immunology, Immunotherapy : CII|January 11, 2020
The CD38<sup>low</sup> natural killer cell line KHYG1 transiently expressing CD16<sup>F158V</sup> in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricideSubhashis Sarkar, Sachin K S Chauhan, John Daly, et al.
Cancers|April 13, 2023
Sialofucosylation Enables Platelet Binding to Myeloma Cells via P-Selectin and Suppresses NK Cell-Mediated CytotoxicityAlessandro Natoni, Marina Cerreto, Maria Stefania De Propris, et al.
Oncoimmunology|February 8, 2021
Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosisSerika D Naicker, Claire L Feerick, Kevin Lynch, et al.
British Journal of Haematology|February 15, 2022
Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019Dawn Swan, Patrick J Hayden, Dirk-Jan Eikema, et al.
Pageof 4